Abstract
BackgroundEfficacy and good tolerability of Rituximab (Rtm) in some refractory to standard care systemic autoimmune rheumatic diseases (SARD) has been demonstrated in several registers (1-3). Although, available evidence is not...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
